Dr Hans Langedijk | Director of Subunit Vaccine Design
Janssen Vaccines & Prevention B.V. | Netherlands

Dr Hans Langedijk, Director of Subunit Vaccine Design, Janssen Vaccines & Prevention B.V.

Hans (JPM) Langedijk currently holds the position of Scientific Director of the Subunit Vaccine Design team, part of Viral Vaccines department at Janssen Vaccines and Prevention. He has set up a protein chemistry group and is responsible for the design and development of novel protein vaccine components against HIV, RSV, Influenza and other viral targets. Two designs have entered the clinic.
Hans is a biochemist by training and received his PhD in 1993 at the University of Amsterdam. From 2002-2010 he worked at Pepscan Therapeutics as project leader MAb development and external projects mostly relating to miniprotein design. He was principal investigator on grants from several European Union framework programs and the Bill & Melinda Gates foundation in which he was involved in epitope mapping and HIV antigen design. Before joining Pepscan he worked at the Institute of Animal Science and Health (Lelystad, 1993-2002) on structure – function relationships of viral surface proteins. In 1997-1998 he worked as a visiting scientist in the structural virology department of J. Johnson at The Scripps Research Institute in La Jolla, USA. He (co)-authored more than 75 peer reviewed scientific articles, many patent applications and joined thesis committees.
Past and present research activities have focused on integration of combinatorial chemistry, bioinformatics, protein engineering and structure-function relation based protein research. Due to the non-academic environment, the research topics have been very broad: structural biology of retroviruses, paramyxoviruses, flaviviruses, amyloids, neuron – chip interaction, transport peptides and oncology. 


DC Pre-congress WS day April 2 @ 09:00

Advances in using structure-based knowledge for smarter vaccine designs

Structure-based vaccines are designed on the rationale that protective epitopes should be sufficient to induce immune responses and provide protection against pathogens, with multiple epitopes inducing a higher immune response. Structure-based vaccines have become a much-anticipated field over the years with increasingly more preclinical and clinical staged developments. This workshop focuses on recent advances and their application in providing protection against infectious diseases.

Progress in Stabilized Pre-fusion Glycoprotein Vaccines for Paramyxoviruses & HIV-1

Using structural based vaccine design to target flavivirus infections: Zika and Dengue

GSK’s CMV structural biology research

Discussion with all speakers

back to speakers